PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA

Turkstra, ErikaBettington, EmilieDonohue, Maria LMervin, Merehau C2022-05-190266-4623http://hdl.handle.net/1885/265568Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliableapplication/pdfen-AU© 2017 The authorsReimbursementHealth budgetResource allocationPharmaceutical Benefits Advisory CommitteeBudget impact analysisPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA201710.1017/S02664623170006172020-12-27